Pluristyx Secures $1.4M from Breakthrough T1D to Develop Universal Immune-Cloaked Cell Line for Type 1 Diabetes Therapies
核心洞察
Pluristyx (搜索) announced a $1.4 million collaboration with Breakthrough T1D (搜索) to create genetically engineered induced pluripotent stem cells for type 1 diabetes (搜索) islet replacement therapies.
The project aims to develop "immune-cloaked" and safety switch-enabled cell lines that could eliminate the need for chronic immunosuppressive drugs in cell replacement therapy.
The technology addresses a major barrier to widespread T1D (搜索) cures by creating universal donor cells that don't require HLA (搜索) matching and can be safely eliminated if needed.
Pluristyx (搜索) announced a $1.4 million collaboration with Breakthrough T1D (搜索) to develop genetically engineered induced pluripotent stem cells (iPSCs) that could revolutionize type 1 diabetes (搜索) treatment by eliminating the need for chronic immunosuppressive drugs. The project addresses one of the most significant barriers to widespread T1D (搜索) cures—the lack of a commercially feasible cell source for manufacturing next-generation islet replacement therapies.
Addressing Current Treatment Limitations
Current islet cell replacement therapies, despite showing clinical trial successes, are limited to a small patient population due to the requirement for chronic immunosuppressive drugs to prevent rejection. These immunosuppressive regimens carry significant risks that exclude most people living with T1D (搜索), particularly children, from accessing potentially curative treatments.
"The development of cell therapies that work for everyone with T1D (搜索) without the need for chronic immunosuppression is a priority for Breakthrough T1D (搜索)," said Sanjoy Dutta, Ph.D., Breakthrough T1D Chief Scientific Officer. "We look forward to the potential of Pluristyx (搜索)'s innovative platform and approach to move us one step closer to making cell therapies a reality for the entire type 1 diabetes (搜索) community."
Innovative Platform Technologies
The collaboration will integrate three key Pluristyx (搜索) technologies into an FDA Drug Master File registered cell line:
iACT (搜索)™ (Induced Allogeneic Cell Tolerance) represents a patented "cloaking" technology that allows cells to evade immune system recognition without disrupting human leukocyte antigen (搜索) (HLA (搜索)) expression. This enables the creation of "universal" allogeneic cells that don't require HLA matching to individual patients.
FailSafe (搜索)® provides a drug-inducible safety switch mechanism that allows selective elimination of unwanted proliferating cells post-transplantation through administration of a safe, inexpensive, globally approved drug available in both oral and IV formats.
PSXi (Pluristyx (搜索) Pluripotent Stem Cells), specifically the PSXi013 line registered under an FDA Drug Master File, serves as a proprietary polyclonal iPSC line designed to support complex genetic engineering while maintaining genetic stability and differentiation capacity during large-scale pharmaceutical manufacturing.
Clinical Impact and Accessibility
The engineered iPSC line will serve as renewable starting material for developing "off-the-shelf" allogeneic therapies that don't require chronic immune suppression. This approach could enable safer, more accessible, and truly curative treatments for people living with T1D (搜索).
"Our goal is to make and provide a safe, universal cell line to groups developing next-generation islet therapies," said Dr. Benjamin Fryer, CEO of Pluristyx (搜索). "Doing so may help make curative treatments accessible to all people living with type 1 diabetes (搜索), including children, without the need for immunosuppressive drugs."
Global Disease Burden
Type 1 diabetes (搜索) affects 9.5 million people globally as an autoimmune condition that causes the pancreas to produce little to no insulin. This leads to dependence on insulin therapy and risks of both short and long-term complications, including blood sugar fluctuations and damage to kidneys, eyes, nerves, and heart. Contrary to common belief, nearly 50% of all T1D (搜索) diagnoses occur in adulthood, and the condition has no connection to diet or lifestyle factors.
The collaboration represents a significant step toward addressing the unmet medical need for safer, more accessible cell replacement therapies that could benefit the entire type 1 diabetes (搜索) community without the limitations of current immunosuppressive approaches.